Skip to main content
Top

2006 | OriginalPaper | Hoofdstuk

Astmabehandeling bij kinderen: meer dan alleen puffen?

Auteurs : prof.dr. C.P. van Schayck, A. Nijholt

Gepubliceerd in: Vademecum permanente nascholing huisartsen

Uitgeverij: Bohn Stafleu van Loghum

share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Samenvatting

Astma is een recidiverende aanvalsgewijs optredende bronchusobstructie op basis van een verhoogde gevoeligheid van de luchtwegen voor specifieke (allergische) en niet-specifieke prikkels. Het reageren op niet-specifieke prikkels (prikkels als lichamelijke inspanning, rook, mist en kou) wordt bronchiale hyperreactiviteit genoemd. De belangrijkste maatregel is het vermijden van niet-specifieke prikkels; niet roken in de omgeving van het kind of door het kind zelf.
Literatuur
go back to reference Dirksen WJ, Geijer RM, Haan M de, et al. NHG-Standaard Astma bij Kinderen (eerste herziening). Huisarts Wet 1998; 41: 130-43. Dirksen WJ, Geijer RM, Haan M de, et al. NHG-Standaard Astma bij Kinderen (eerste herziening). Huisarts Wet 1998; 41: 130-43.
go back to reference Knorr B, Franchi LM, Bisgaard H, et al. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2-5 yaers. Pediatrics 2001; 108: E48. Knorr B, Franchi LM, Bisgaard H, et al. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2-5 yaers. Pediatrics 2001; 108: E48.
go back to reference Bisgaard H. Montelukast for viral respiratory infection-induced exacerbations of asthma. Am J respire Crit Care Med 2005; 172: 783-84. Bisgaard H. Montelukast for viral respiratory infection-induced exacerbations of asthma. Am J respire Crit Care Med 2005; 172: 783-84.
go back to reference Bisgaard H, Zielen S, Garcia-Garcia ML, et al. Montelukast reduces asthma exacerbations in 2-to 5 year- old children with intermittent asthma. Am J Respir Crit Care Med 2005; 171: 315-22. Bisgaard H, Zielen S, Garcia-Garcia ML, et al. Montelukast reduces asthma exacerbations in 2-to 5 year- old children with intermittent asthma. Am J Respir Crit Care Med 2005; 171: 315-22.
go back to reference Luskin A, Bukstein D, Kocevar VS, et al. Asthma rescue and allergy medication use among asthmatic children with prior allergy prescriptions who initiated asthma controller therapy. Ann Allergy Asthma Immunol 2005; 95: 129-36. Luskin A, Bukstein D, Kocevar VS, et al. Asthma rescue and allergy medication use among asthmatic children with prior allergy prescriptions who initiated asthma controller therapy. Ann Allergy Asthma Immunol 2005; 95: 129-36.
go back to reference Melo RE, Sole D, Naspitz CK. Exercise-induced bronchoconstriction in children: montelukast attenuates the immediate-phase and late-phase responses. J. Allergy Clin Immunol 2003; 111: 301-307. Melo RE, Sole D, Naspitz CK. Exercise-induced bronchoconstriction in children: montelukast attenuates the immediate-phase and late-phase responses. J. Allergy Clin Immunol 2003; 111: 301-307.
go back to reference Kemp JP, Dockhorn RJ, Shapiro GG, et al. Montelukast once daily inhibits excercise-induced bronchocontriction in 6- to 14-year-old children with asthma. J Pediatr 1998; 133: 424-28. Kemp JP, Dockhorn RJ, Shapiro GG, et al. Montelukast once daily inhibits excercise-induced bronchocontriction in 6- to 14-year-old children with asthma. J Pediatr 1998; 133: 424-28.
go back to reference Kim JH, Lee SY, Kim HB, et al. Prolonged effect of montelukast in asthmatic children with exercised induced bronchoconstriction. Paed Pulmonol 2005; 39: 162-66. Kim JH, Lee SY, Kim HB, et al. Prolonged effect of montelukast in asthmatic children with exercised induced bronchoconstriction. Paed Pulmonol 2005; 39: 162-66.
go back to reference Maspero JF, Duenas-Meza E, Volovitz B, et al. Oral montelukast versus inhaled beclomethasone in 6- to 11-year-old children with asthma: results of an open-label extension study evaluating long-term safety, satisfaction, and adherence with therapy. Curr Med Res Opinions 2001; 17: 96-104. Maspero JF, Duenas-Meza E, Volovitz B, et al. Oral montelukast versus inhaled beclomethasone in 6- to 11-year-old children with asthma: results of an open-label extension study evaluating long-term safety, satisfaction, and adherence with therapy. Curr Med Res Opinions 2001; 17: 96-104.
go back to reference Zeiger RS, Szefler SJ, Phillips BR, et al. Response profiles to fluticasone and montelukast in mild-to-moderate pesistent childhood asthma. J Allergy Clin Immunol 2006; 117: 45-52. Zeiger RS, Szefler SJ, Phillips BR, et al. Response profiles to fluticasone and montelukast in mild-to-moderate pesistent childhood asthma. J Allergy Clin Immunol 2006; 117: 45-52.
go back to reference Szefler SJ, Phillips BR, Martinez FD, et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol 2005; 115: 233-42. Szefler SJ, Phillips BR, Martinez FD, et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol 2005; 115: 233-42.
go back to reference Garcia Garcia ML, Wahn U, Gilles L, et al. Montelukast, compared with fluticasone, for control of asthma among 6- to 14-year-old patients with mild asthma: the mosaic study. Paediatrics 2005; 116: 360-69. Garcia Garcia ML, Wahn U, Gilles L, et al. Montelukast, compared with fluticasone, for control of asthma among 6- to 14-year-old patients with mild asthma: the mosaic study. Paediatrics 2005; 116: 360-69.
go back to reference Richtlijn 'Astmabehandeling bij kinderen' van kinderlongartsen (2e herziening). II. Medicamenteuze behandeling. Ned Tijdschr Geneeskd 2003; 147: 1909-13. Richtlijn 'Astmabehandeling bij kinderen' van kinderlongartsen (2e herziening). II. Medicamenteuze behandeling. Ned Tijdschr Geneeskd 2003; 147: 1909-13.
go back to reference Holgate ST, Djukanovic R, Casale T, Bousquet J. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy. Clin Exp Allergy 2005; 35: 408-16. Holgate ST, Djukanovic R, Casale T, Bousquet J. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy. Clin Exp Allergy 2005; 35: 408-16.
go back to reference Holgate S, Casale T, Wenzel S, et al. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol 2005; 115: 459-65. Holgate S, Casale T, Wenzel S, et al. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol 2005; 115: 459-65.
go back to reference Oba Y, Salzman GA. Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate to severe allergic asthma. J Allergy Clin Immunol 2004; 114: 265-69. Oba Y, Salzman GA. Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate to severe allergic asthma. J Allergy Clin Immunol 2004; 114: 265-69.
Metagegevens
Titel
Astmabehandeling bij kinderen: meer dan alleen puffen?
Auteurs
prof.dr. C.P. van Schayck
A. Nijholt
Copyright
2006
Uitgeverij
Bohn Stafleu van Loghum
DOI
https://doi.org/10.1007/978-90-313-8808-0_1386